Savara (NASDAQ:SVRA) Shares Gap Up Following Analyst Upgrade

Savara Inc (NASDAQ:SVRA) gapped up prior to trading on Wednesday after Guggenheim raised their price target on the stock from $8.00 to $10.00. The stock had previously closed at $3.80, but opened at $4.42. Guggenheim currently has a buy rating on the stock. Savara shares last traded at $3.89, with a volume of 12,854,905 shares trading hands.

Other equities analysts also recently issued research reports about the company. Evercore ISI dropped their price target on Savara from $10.00 to $7.00 and set an “outperform” rating on the stock in a research report on Thursday, May 16th. Oppenheimer raised their target price on shares of Savara from $11.00 to $15.00 and gave the company an “outperform” rating in a research report on Wednesday. Piper Sandler upped their price target on shares of Savara from $7.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. HC Wainwright lifted their price objective on shares of Savara from $6.00 to $10.00 and gave the company a “buy” rating in a report on Thursday. Finally, JMP Securities reissued a “market outperform” rating and issued a $8.00 price objective on shares of Savara in a research note on Monday, May 6th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $11.00.

Institutional Trading of Savara

Institutional investors have recently modified their holdings of the company. Superstring Capital Management LP purchased a new stake in Savara during the fourth quarter valued at approximately $3,827,000. Adage Capital Partners GP L.L.C. boosted its position in shares of Savara by 30.9% in the 3rd quarter. Adage Capital Partners GP L.L.C. now owns 7,938,551 shares of the company’s stock worth $30,008,000 after purchasing an additional 1,874,000 shares in the last quarter. Polar Capital Holdings Plc acquired a new stake in shares of Savara in the 3rd quarter worth $3,780,000. Jennison Associates LLC grew its stake in Savara by 128.0% during the 4th quarter. Jennison Associates LLC now owns 8,815,358 shares of the company’s stock worth $41,432,000 after buying an additional 4,948,596 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. acquired a new position in Savara during the 4th quarter valued at about $74,000. 87.93% of the stock is currently owned by institutional investors.

Savara Stock Performance

The company has a quick ratio of 14.90, a current ratio of 14.90 and a debt-to-equity ratio of 0.22. The company has a market capitalization of $526.50 million, a PE ratio of -10.30 and a beta of 0.70. The business has a 50 day simple moving average of $4.32 and a 200 day simple moving average of $4.63.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). Equities research analysts predict that Savara Inc will post -0.41 EPS for the current fiscal year.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.